Condition: Graves Disease · Hyperthyroidism/Thyrotoxicosis · Sponsor: THYROSCOPE INC.
This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating these measurements with free T4 levels obtained through serial blood testing. No investigational device output will be disclosed to participants, and the study will not alter standard clinical care.
This description comes directly from the study's public registry record.
Jun An · +82 10-2849-0041 · jun.an@thyroscope.com
Jae Hoon Moon, MD, PhD · +82-10-5105-9815 · jaehoon.moon@thyroscope.com
Always discuss trial participation with your own doctor first.
| Umesh Masharani | San Francisco, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07017907